Core Viewpoint - The company reported a decrease in revenue for the six months ending June 30, 2025, compared to the same period in 2024, but showed signs of recovery and growth in the latter half of 2025 [1] Financial Performance - Revenue decreased from RMB 60.8 million for the six months ending June 30, 2024, to RMB 53.2 million for the same period in 2025, a reduction of RMB 7.6 million [1] - The loss for the period decreased from RMB 167 million for the six months ending June 30, 2024, to RMB 76.4 million for the same period in 2025, a reduction of RMB 90.6 million [1] Market Dynamics - The inclusion of the drug Cevinostat (希维奥®) in the 2023 National Medical Insurance Directory in December 2023 initially drove strong market growth expectations for the six months ending June 30, 2024 [1] - Market demand gradually returned to a rational state after the initial surge [1] - Revenue for the six months ending June 30, 2025, increased by RMB 22 million compared to the second half of 2024, indicating steady growth and stability [1]
德琪医药-B(06996.HK)上半年期内亏损收窄至7640万元